Published August 28, 2026
Every morning our data team scans the GLP-1 wire for stories that will actually matter to people who eat on these medications. This one — 'Semaglutide cut cardiovascular inflammation marker CRP by…', from a news source on 2026-09-02 — made the cut, and the analysis below connects it to the food data rather than repeating the press release.
This story is on our radar. We cover GLP-1 news by checking the source and translating only the food-relevant part into the site's usual terms — protein, fiber and fat. Where a story makes food claims, the USDA data is the referee.
What ties GLP-1 coverage together is a small set of food variables that keep resurfacing: protein protects the muscle you want to keep, fat is the strongest predictor of nausea on a slowed stomach, and fiber plus water manages constipation. This site's verdict system was built around those three because they are the ones that actually move outcomes.
Headlines rotate; the food math does not. A story about heart outcomes and a story about muscle loss both land on the same plate guidance, which is why this site keeps its verdict labels stable — the reference should not wobble with the news cycle.
The honest limit: clinical stories are for clinicians. Food data answers 'what is in the food'; whether a headline applies to your dose, your body, or your treatment is a question for your healthcare provider. This post stays on the food side of that line, and says so out loud.
How we decide what to cover: the story has to be recent, traceable to a named source, and relevant to people who eat on a GLP-1. We skip the rumor layer entirely — if it cannot be linked, it does not get a page. That filter is the same one the site applies to food data, and it keeps the archive consistent over time.
The practical read of this story is simple: traceable sources and food data.
The plate does not change with the headline: protein anchors, vegetables fill, heavy food is portioned, water is constant.
Side-effect stories point to the two food levers — lower fat for nausea, more fiber plus water for constipation; outcome stories point to the same plate, day after day.
A headline is not a prescription: questions about your own dose or symptoms belong with your healthcare provider.
A day of eating is a sample; a week is the pattern. The people who do well on GLP-1s are consistent at the week level, which is why this site judges food in weekly terms rather than meal by meal. The week is long enough to show the trend and short enough to act on it.
The portion template: a palm of protein, a half-plate of produce, and a small quarter for the heavier item. It is the same proportion at every meal. It is the default plate the scoring system would hand you if you asked.
If a food reliably makes you sick across several tries, that is useful information — the answer is to change the pattern, not to power through. Smaller portions, plainer preparation, and earlier-in-the-day timing cover most of the cases the data explains. And if symptoms like nausea, vomiting or constipation persist despite the food-side fixes, that is a conversation for your healthcare provider. This site rates foods; your clinician manages your treatment. Both sides matter, and neither replaces the other. That clarity protects readers and keeps the advice trustworthy, page after page.
Relevance is mostly indirect: a study changes which nutrient gets attention, not the food pattern itself. The pattern — protein first, portions small, fiber and water constant — survives every headline, and the scoring criteria are the reference for whichever nutrient the story highlights. Your dose and treatment questions remain your clinician's job.
No headline changes the data on this site. Food verdicts come from USDA values and guideline frameworks, not from any single story — a study can update the framework, but a single news cycle does not move the per-100g numbers. Patterns, not panic, are the response, and the pattern is the same plate: protein first, vegetables second, heavy food in small servings, water throughout.
Check the source, the date, and whether a named study or agency stands behind it — FDA, peer-reviewed journals such as JAMA and NEJM, and established health media. Beware of headlines that name no study and link to no source, and of stories that overstate a single trial. This post links its source openly; that is the same bar we hold ourselves to, and the same bar we suggest for anything you read.
Weekly is a good rhythm. The plate guidance shifts slowly, so there is no advantage to reading every headline the day it lands; the stable verdicts here cover the food side regardless. If a story does affect your treatment, the right next step is a conversation with your provider, not another article.
Source: a news source · 2026-09-02. We link the source and stay on the food side; study details we have not read in full are not restated here.
The numbers above are traceable the same way each food we score is: back to USDA and to the named framework. This is one entry in a site that checks its claims the same way every day.
This one came across our desk from Trial synthesis: Lancet May 2026 + Am J Psychiatry Jul 2026 via GLP3 Planne
990 adverse-event reports on compounded semaglutide: what…The headline first: '990 adverse-event reports on compounded semaglutide: what…', reported by a news
What happens to weight after stopping GLP-1s: a Cleveland…We follow the GLP-1 news the way we follow food data: note the source, check the claims, and write only what c